Related references
Note: Only part of the references are listed.Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan et al.
CELL (2011)
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
Vandana Abramson et al.
CLINICAL CANCER RESEARCH (2011)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al.
LANCET ONCOLOGY (2011)
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells
Faiyaz Notta et al.
NATURE (2011)
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
Zhe Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome
Johan Staaf et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Daniele Merico et al.
PLOS ONE (2010)
Transcriptional Regulation of Estrogen Receptor-α by p53 in Human Breast Cancer Cells
Stephanie Harkey Shirley et al.
CANCER RESEARCH (2009)
The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells
Angelo Cicalese et al.
CELL (2009)
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Miguel Martin et al.
ONCOLOGIST (2009)
Cancer Stem Cells in Solid Tumors: An Overview
Catherine Adell O'Brien et al.
SEMINARS IN RADIATION ONCOLOGY (2009)
The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis
Francois Vaillant et al.
CANCER RESEARCH (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Her2-positive breast cancer: Herceptin and beyond
Windy Dean-Colomb et al.
EUROPEAN JOURNAL OF CANCER (2008)
Direct multiplexed measurement of gene expression with color-coded probe pairs
Gary K. Geiss et al.
NATURE BIOTECHNOLOGY (2008)
Stromal gene expression predicts clinical outcome in breast cancer
Greg Finak et al.
NATURE MEDICINE (2008)
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
H. Korkaya et al.
ONCOGENE (2008)
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor
C. Osipo et al.
ONCOGENE (2008)
Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-Induced mammary tumors
Jeff C. Liu et al.
CANCER RESEARCH (2007)
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses
Maciej Kmieciak et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
The prognostic role of a gene signature from tumorigenic breast-cancer cells.
Rui Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival
M Reedijk et al.
CANCER RESEARCH (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
